SCHEMBL24314267

SCHEMBL24314267

C=C[C@H]1C[C@@H](n2cc(Br)c3c(Cl)ncnc32)[C@@H]2OC(C)(C)O[C@@H]21

nearest known ligand 0.43

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
▸ ADK P55263 7/20 0.43
▸ METTL3 Q86U44 2/20 0.34
▸ AHCY P23526 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20488512 0.90 ADK (0.43) ADKMETTL3AHCY
SCHEMBL23323202 0.88 PRMT5 (0.34) ADKAHCY
SCHEMBL23273847 0.86 ADK (0.30) ADKAHCY
SCHEMBL23273904 0.86 ADK (0.30) ADKAHCY
SCHEMBL17549888 0.85 HTR2B (0.31) ADKAHCY
SCHEMBL30941168 0.82 ADK (0.46) ADKMETTL3
SCHEMBL25046663 0.82 ADK (0.46) ADKMETTL3
SCHEMBL25048642 0.80 ADK (0.42) ADKMETTL3AHCY
SCHEMBL31617994 0.79 ADK (0.44) ADKMETTL3
SCHEMBL31617998 0.79 ADK (0.44) ADKMETTL3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240051985-A1 METTL3 MODULATORS ACCENT THERAPEUTICS INC (US) 2024-02-15 — — US disclosed
EP-4229067-A1 METTL3 MODULATORS Accent Therapeutics, Inc. (US) 2023-08-23 — — EP disclosed
WO-2022081739-A1 METTL3 MODULATORS ACCENT THERAPEUTICS, INC. (US) 2022-04-21 — — WO disclosed
WO-2022081739-A1 METTL3 MODULATORS ACCENT THERAPEUTICS, INC. (US) 2022-04-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240051985-A1 METTL3 MODULATORS METTL3, METTL16, METTL14 ADK 1475/4885METTL3 1/4885AHCY 496/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback